A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas

Name: A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas
Published: 2019
License: Public Domain

Innovent Biologics (Suzhou) Co. Ltd. · 2019

ClinicalTrials.gov · Datasets · License: Public Domain · 2019

Open Source ↗

advanced malignancies, interventional, phase1

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas

Related documents